LAUSR

M. A. Stevenson, J. Rostas, P. Philips, Y. Li, S. P. Li, H. Pandit and R. C. G. Martin * Corresponding author. Megan Stevenson, University of Louisville School of Medicine, USA Background: Thermal ablation for various malignant tumors has emerged as an effective treatment modality for neoplasms not amenable to resection. Several newer 2450 MHz modalities for microwave ablation (MWA) exist and the purpose of this study was to compare the Solero to the Sulis V pMTA and NeuWave Certus 140 systems, with regard to equivalence for safety and efficacy. Methods: In this Institutional Animal Care, Good Laboratory Practice (GLP) study, fifteen pigs underwent ablations of the liver, kidney and lung with either the Solero, Sulis or NeuWave. Animals were monitored for adverse events (AEs) perioperatively and MRI was performed on days 0 and 28 to measure the zone of ablation (ZA). Results: The Solero safety profile was similar to both Sulis and NeuWave (p = 0.32 and 0.62, respectively). Solero also had equivalent efficacy to Sulis and NeuWave (ZA) (day 0, p = 0.18 and 0.09, respectively; day 28, p = 0.78 and 0.18, respectively). Solero achieved this ZA with a statistically significant increased wattage in less time when compared to NeuWave (p = 0.03 and 0.00, respectively). Conclusion: The Solero has equivalent safety and efficacy profiles compared to the Sulis and NeuWave systems. It additionally was more time-efficient in achieving similar ablation defects when compared to the NeuWave. It should be considered as an option for treatment ofmalignant lesions of the liver, lung and kidney. Further large-scale studies are needed to determine long-term oncologic outcomes.